Serum levels of soluble CD23 in patients with bullous pemphigoid. 1995

N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
Department of Dermatology, Kansai Medical University, Osaka, Japan.

In this study, we tested the serum levels of soluble CD23 (sCD23) in 27 bullous pemphigoid (BP) patients and compared them with the disease activity. Soluble CD23 is the cleaved portion of the low affinity Fc receptor for IgE (Fc epsilon RII/CD23) which has an affinity for IgE and regulates IgE synthesis. Although bullous pemphigoid (BP) is a subepidermal blistering disease characterized by IgG class autoantibodies against the basement membrane of stratified squamous epithelia, several IgE-related phenomena have been reported. Recently, we have shown that Fc epsilon RII-expressing and IgE-bearing cells are detectable in the lesional skin and concluded that an IgE-Fc epsilon RII/CD23 system may be involved in the pathogenesis of this disease. The serum level of sCD23 in BP patients was significantly higher than healthy controls (p < 0.01). In 11 out of 12 patients, the alteration of serum sCD23 levels correlated well with the disease activity. Thus the serum level of sCD23 is useful as a new parameter for assessing the level of disease activity in BP. High levels of sCD23 may represent part of an IgE-mediated immune reaction which may play a role in the pathogenesis of BP.

UI MeSH Term Description Entries
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D008297 Male Males
D010391 Pemphigoid, Bullous A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis. Pemphigoid,Bullous Pemphigoid,Pemphigoids
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
April 1994, Journal of dermatological science,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
August 1995, Archives of dermatology,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
January 1985, Acta dermato-venereologica,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
January 2012, European journal of dermatology : EJD,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
August 1994, Clinical and experimental immunology,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
April 2007, Journal of dermatological science,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
October 1996, Immunology letters,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
March 2007, The British journal of dermatology,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
June 2004, Journal of dermatological science,
N Maekawa, and H Hosokawa, and H Soh, and M Kasahara, and H Izumi, and J Yodoi, and Y Asada
January 2007, Dermatology (Basel, Switzerland),
Copied contents to your clipboard!